[{"indications": "Indications\u00a0chronic hepatitis B infection with either compensated\r\nliver disease with evidence of viral replication, and histologically\r\ndocumented active liver inflammation and fibrosis or decompensated liver disease ", "name": "ADEFOVIR DIPIVOXIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.3 Viral hepatitis", "5.3.3.1 Chronic hepatitis B"], "cautions": "Cautions\u00a0monitor liver function tests every 3\r\nmonths, and viral markers for hepatitis B every 3\u20136 months during\r\ntreatment (continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation); monitor renal function before treatment then every 3 months, more frequently in renal impairment or in patients receiving nephrotoxic\r\ndrugs; elderly; discontinue\r\nif deterioration in liver function, hepatic steatosis, progressive\r\nhepatomegaly or unexplained lactic acidosis", "side-effects": "Side-effects\u00a0nausea, vomiting, dyspepsia, abdominal pain, flatulence,\r\ndiarrhoea; asthenia, headache; renal failure; hypophosphataemia; rash\r\nand pruritus; also reported pancreatitis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/127968.htm", "doses": ["adult over 18 years, 10\u00a0mg\r\nonce daily"], "pregnancy": "Pregnancy\u00a0toxicity in animal studies\u2014manufacturer\r\nadvises use only if potential benefit outweighs risk; effective contraception\r\nrequired during treatment"}]